Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results
Publishing timestamp: 2024-07-25 08:45:28
Summary
Roche's weight loss drugs show promising early stage trial results, aiming to combat obesity and associated health risks. The company believes they have a competitive edge in the growing obesity medication market and is open to further acquisitions to strengthen their portfolio. Analysts are looking forward to more trial data in September.
Sentiment: POSITIVE
Tickers: NOVO.B-DK,
Keywords: novo nordisk a/s, business news, biotechnology, biotech and pharmaceuticals, pharmaceuticals,